Real-world data confirm Mvasi's safety as a cost-effective alternative to reference bevacizumab (Avastin) for treating retinal conditions.

Video webcast now available on-demand ISELIN, N.J., July 22, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care ...

Domestic researchers have found for the first time in the world that immuno-cancer drugs atetzolizumab plus bevacizumab ...

Fewer than half of eligible patients with advanced ovarian cancer receive first-line maintenance treatments, highlighting ...

Despite efforts to try to get this medication for free, Angela has to pay for it privately because the National Institute for Health and Care Excellence (NICE) says she is not eligible.

Cardiff Oncology's onvansertib shows a 64% response rate in early colorectal cancer trials. Click here to read an analysis of ...

Introduction: Bevacizumab, a humanized monoclonal anti-vascular endothelial growth factor antibody, was FDA approved in 2009 for progressive glioblastoma. Phase II clinical trials suggested an ...

The updated guidelines from American Society for Radiation Oncology also address the treatment of older and medically frail ...

Age-Related Macular Degeneration Market Epidemiology Report 2025-2035: Drugs Pipeline, Therapies, and Forecast The report provides a detail ...

Adding atezolizumab and bevacizumab to TACE can improve outcomes in previously untreated, unresectable HCC, data suggest.

Pembrolizumab, an anti-programmed death receptor-1 (PD-1) therapy, is currently approved under the brand name Keytruda ® for other gynecological cancers, including cervical cancer and endometrial ...

The response rate was higher in those with a KRAS mutation at 44%, compared to 17% in KRAS wild-type patients.